logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Nong Xu

hefei university
H指数:30
被引数:7,557
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial

卡瑞利珠单抗联合SOX化疗作为病理分期III期胃或胃食管结合部腺癌的辅助治疗：一项前瞻性、多中心、单臂、II期试验

Therapeutic Advances in Medical Oncology
IF4.2
2025-07-100
OA
Hailong Jin; Jiren Yu; Yuan Gao; Xiaosun Liu; Hongtao Xu; Haiping Jiang; Shenkang Zhou; Nong Xu; Yulong Zheng; Qianyun Shen; Zhicheng Zhao; Dan Wu; Qing Zhang; Kankai Zhu
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

针对晚期肿瘤患者的PD-1和PD-L1的一流双特异性抗体IBI318 (LY3434172): Ia/Ib期研究

JOURNAL OF HEMATOLOGY & ONCOLOGY
IF40.4
2024-11-290
OAAI
Ruan, Dan-Yun; Wei, Xiao-Li; Liu, Fu-Rong; Hu, Xi-Chun; Zhang, Jian; Ji, Dong-Mei; Huang, Ding-Zhi; Zhao, Yan-Qiu; Pan, Hong-Min; Liao, Wang-Jun; Yang, Kun-Yu; Xu, Nong; Lu, Xiao-Xiao; Chen, Yu-Ling; Zhang, Wen; Zhou, Hui; Zhao, Hong-Yun; Xu, Rui-Hua
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

基于SALIRI的 (雷替曲塞联合伊立替康) 疗法作为转移性结直肠癌患者的二线治疗 (SALLY): 一项前瞻性，多中心，非干预性，注册研究

CANCER COMMUNICATIONS
IF24.9
2024-07-080
OAAI
Qin, Shuqui; Li, Jin; Zhou, Aiping; Zhang, Yanqiao; Yuan, Xianglin; Zhu, Liangjun; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Wang, Weibo; Liang, Jun; Zhang, Xianwen; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhenyan; Yue, Lu; Fang, Yong; Xiong, Jianping; Yang, Jianwei; Wan, Yiye; Yin, Xianli; Wang, Wenling; Xu, Nong; Wang, Xiaohong; Xiao, Zemin; Su, Huafang; Wang, Ying; Gu, Kangsheng; Tu, Shuiping; Wang, Zishu; Liu, Bo; Hu, Xiaohua; Liu, Weixian; Li, Xiaofeng
'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)
EUROPEAN JOURNAL OF CANCER
IF7.1
2023-01-010
PRE
Li, Jiarui; Cheng, Yuejuan; Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Chi, Yihebali; Yu, Xianjun; Li, Enxiao; Xu, Nong; Liu, Tianshu; Lou, Wenhui; Bai, Yuxian; Yuan, Xianglin; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Guan, Sha; Fan, Songhua; Su, Weiguo
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

基线放射学特征可作为接受surufatinib治疗的胰腺神经内分泌肿瘤肝转移患者疗效的预测指标

CHINESE JOURNAL OF CANCER RESEARCH
IF6.3
2023-01-013
OA
Zhang, Jianwei; Zhu, Haibin; Shen, Lin; Li, Jie; Zhang, Xiaoyan; Bai, Chunmei; Zhou, Zhiwei; Yu, Xianrui; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Lou, Wenhui; Chi, Yihebali; Xu, Nong; Yin, Yongmei; Bai, Yuxian; Zhang, Tao; Xiu, Dianrong; Chen, Jia; Qin, Shukui; Wang, Xiuwen; Yang, Yujie; Shi, Haoyun; Luo, Xian; Fan, Songhua; Su, Weiguo; Lu, Ming; Xu, Jianming

研究方向

暂未获取到该数据
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
J
Jianming Xu
H 指数:56论文数:387被引数:2.6万
T
Tianshu Liu
H 指数:49论文数:399被引数:1.6万
L
Lin Shen
H 指数:62论文数:826被引数:2.6万
Ying Yuan 封面图
Ying Yuan
H 指数:54论文数:986被引数:1.2万
S
Shukui Qin
H 指数:76论文数:578被引数:5.1万
徐
徐瑞华
H 指数:104论文数:1,466被引数:5.3万
S
Songhua Fan
H 指数:24论文数:91被引数:4,296
W
Weiguo Su
H 指数:23论文数:151被引数:2,592
C
Chenyu Mao
H 指数:17论文数:101被引数:1,159